Dimerix Ltd
DXB
Company Profile
Business description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
Contact
425 Smith Street
FitzroyVIC3065
AUST: +61 1300813321
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
9
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,381.40 | 7.40 | 0.09% |
| CAC 40 | 7,727.93 | 42.55 | -0.55% |
| DAX 40 | 23,344.54 | 257.89 | 1.12% |
| Dow JONES (US) | 41,218.83 | 98.60 | -0.24% |
| FTSE 100 | 8,596.35 | 99.55 | 1.17% |
| HKSE | 22,658.98 | 154.30 | 0.69% |
| NASDAQ | 17,844.24 | 133.49 | -0.74% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,433.93 | 12.68 | 0.10% |
| S&P 500 | 5,650.38 | 36.29 | -0.64% |
| S&P/ASX 200 | 8,163.50 | 5.70 | 0.07% |
| SSE Composite Index | 3,309.95 | 30.91 | 0.94% |